
    
      The trial consists of two groups: IVIg group and control group. Thirty patients will be
      recruited into IVIg group. Thirty Patients who are matched for age, gender, National
      Institutes of Health Stroke Scale scores, hematomal volumes, and locations of hematomas, will
      be selected into control group. Patients in control group just receive standard management,
      while those in IVIg group will receive standard management plus intravenous immunoglobulin
      therapy. The outcome assessor is blinded to the group assignments.
    
  